NCT01876550View on ClinicalTrials.gov

A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.

PHASE1CompletedINTERVENTIONAL
Enrollment

1,902

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

May 6, 2019

Conditions
Secondarily Infected Traumatic Skin Lesions
Interventions
DRUG

Mupirocin Calcium Cream, 2%

Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.

DRUG

Bactroban® Cream

Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.

DRUG

Cream vehicle of test product

Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT01876550 - A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions. | Biotech Hunter | Biotech Hunter